4D pharma (LBPS) News Today → A new way to collect income from stocks (From DTI) (Ad) Free LBPS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadline4D Molecular Therapeutics new overweight at Barclays on genetic medicine platformmsn.com - April 15 at 1:30 PMLancashire: pharmacy robots speed up prescription pickingmsn.com - April 8 at 7:53 AMPROGRESS 2024: In business for more than 60 years, Professional Pharmacy offers a wide range of servicesyahoo.com - March 30 at 10:27 PMNAT-STORY4D-Pharmacy first scheme could free up 30 million GP appointments annuallymsn.com - March 18 at 3:43 PMStrong Buy Recommendation for 4D Molecular Therapeutics Amid Promising 4D-150 Gene Therapy Study Resultsmarkets.businessinsider.com - February 13 at 1:28 PMAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), BridgeBio Pharma (BBIO) and Phibro Animal Health (PAHC)markets.businessinsider.com - February 8 at 10:47 AMBuy Rating for 4D Molecular Therapeutics Backed by Promising 4D-150 Gene Therapy Trial Resultsmarkets.businessinsider.com - February 5 at 3:17 PM4D Molecular Therapeutics Shares Rise 33% After Positive Trial Datamarketwatch.com - February 5 at 10:16 AM4D Molecular Therapeutics GAAP EPS of -$0.24 beats by $0.37, revenue of $20.2M beats by $10.98Mmsn.com - November 9 at 8:14 PM4D Molecular Therapeutics GAAP EPS of -$0.77 misses by $0.01, revenue of $0.24M misses by $0.78Mmsn.com - August 9 at 7:25 PMHuman Microbiome Market worth $1.7 billion by 2029benzinga.com - July 14 at 8:14 PMThe 4D Bioprinting Market is anticipated to grow at a CAGR of around 35% by 2035, claims Roots Analysisbenzinga.com - May 6 at 7:53 PM4D Molecular Therapeutics proposes $100M stock offeringmsn.com - May 4 at 6:54 PM4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimatesmsn.com - March 15 at 8:13 PMHuman Microbiome Market Report 2023-2033finance.yahoo.com - February 7 at 9:39 AMHow Is The Market Feeling About 4D Molecular Therapeutics?msn.com - December 15 at 12:38 PMExpert Ratings for 4D Molecular Therapeuticsmarkets.businessinsider.com - November 18 at 2:16 PMMicrobiome Therapeutics Market to Boom at Robust CAGR to Cross USD 746 Million by 2028 | BlueWeave Consultingbenzinga.com - October 4 at 8:31 PMX4 Pharmaceuticals: Upcoming Catalystsseekingalpha.com - September 20 at 9:29 PM4D pharma stock to be delisted from Nasdaq after co was placed into administrationseekingalpha.com - June 28 at 5:14 PM4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaqfinance.yahoo.com - June 28 at 5:14 PMmarketbeat.com - June 24 at 9:40 AM4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - May 26 at 9:52 PM4D pharma to Present at the H.C. Wainwright Global Investment Conferencefinance.yahoo.com - May 19 at 8:59 PM4D pharma Shares Rise on Encouraging Results From Asthma Treatment Trialmarketwatch.com - May 17 at 6:26 AM4D Pharma Presents Data Supporting Potential Of MRx-4DP0004 As Oral Treatment For Asthmanasdaq.com - May 17 at 6:26 AM4D Pharma has a busy year ahead after a successful 12 months of clinical researchproactiveinvestors.com - April 1 at 8:01 AM4D pharma reports FY resultsseekingalpha.com - March 31 at 10:00 PM4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022finance.yahoo.com - March 31 at 10:00 PM4D pharma stock soars 56% as drug combo meets efficacy goal early in kidney cancer groupseekingalpha.com - March 23 at 12:01 PMmarketbeat.com - March 23 at 9:59 AMmarketbeat.com - March 23 at 9:42 AMACHR,EBON and GENI among pre market gainersseekingalpha.com - March 12 at 9:04 PM4D pharma gets green light for phase I clinical trial of Parkinson's disease candidatesproactiveinvestors.com - February 23 at 11:18 PM4D Pharma To Test Its Single-Strain Live Biotherapeutics In Parkinson's Diseasemsn.com - February 22 at 3:27 PMmarketbeat.com - February 22 at 9:34 AM4D Pharma Shares Rise as Parkinson's Trial Receives FDA Clearancemorningstar.com - February 22 at 8:55 AM4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Diseasefinance.yahoo.com - February 22 at 8:55 AM4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacybenzinga.com - January 28 at 9:03 PM4D Pharma reports additional positive data from Part A of mid-stage asthma drug trialseekingalpha.com - January 27 at 9:16 AM4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthmafinance.yahoo.com - January 27 at 9:16 AM4D pharma hails 'highly encouraging' data from its early-stage asthma trialproactiveinvestors.com - January 27 at 4:15 AM4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004finance.yahoo.com - January 20 at 9:54 AM4d Pharma Plc - ADR Shares Near 52-Week Low - Market Movernasdaq.com - January 8 at 7:39 PM4D pharma plc: 4D pharma to Present at the H.C. Wainwright BioConnect Conferencefinanznachrichten.de - January 5 at 9:39 AM4D pharma to Present at the H.C. Wainwright BioConnect Conferencefinance.yahoo.com - January 5 at 9:39 AM4D pharma 'couldn't have hoped for more at this stage' from live biotherapeutic for asthmaproactiveinvestors.com - December 14 at 7:04 AM4D pharma says asthma live biotherapeutic shows ‘promising’ early signs of clinical activityproactiveinvestors.com - December 13 at 8:04 AM4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthmafinance.yahoo.com - December 13 at 8:04 AM4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021finance.yahoo.com - December 9 at 8:15 AM Get 4D pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LBPS and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now LBPS Media Mentions By Week LBPS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LBPS News Sentiment▼0.000.42▲Average Medical News Sentiment LBPS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LBPS Articles This Week▼00▲LBPS Articles Average Week Get 4D pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LBPS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CNTX News GRFS News LVTX News NLSP News PHVS News TLSA News ACONW News DRTSW News AONC News ARTLW News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LBPS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
